Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Addex Therapeutics Ltd ADR (ADXN)

Addex Therapeutics Ltd ADR (ADXN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,307
  • Shares Outstanding, K 1,060
  • Annual Sales, $ 1,800 K
  • Annual Income, $ -11,760 K
  • 60-Month Beta 1.77
  • Price/Sales 4.75
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ADXN with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -5.00
  • Growth Rate Est. (year over year) +20,080.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.50 +4.53%
on 06/17/24
9.56 -17.99%
on 06/05/24
-0.76 (-8.84%)
since 05/31/24
3-Month
7.50 +4.53%
on 04/29/24
27.90 -71.90%
on 04/09/24
-5.40 (-40.79%)
since 04/02/24
52-Week
5.00 +56.80%
on 12/15/23
27.90 -71.90%
on 04/09/24
-2.58 (-24.76%)
since 06/30/23

Most Recent Stories

More News
Addex Completes $4.2 Million Equity Financing

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 26, 2022 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage...

ADXN : 7.84 (+0.06%)
Addex Shareholders Approve All Resolutions at Annual General Meeting

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 10, 2022 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company...

ADXN : 7.84 (+0.06%)
Addex Reports Q1 2022 Financial Results

CHF14.9M ($16.1M) of cash and cash equivalents at March 31, 2022Dipraglurant Phase 2 blepharospasm clinical trial on track to report data in Q2 2022Phase...

ADXN : 7.84 (+0.06%)
Addex Convenes Annual General Meeting 2022

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, March 31, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage...

ADXN : 7.84 (+0.06%)
Addex to Present at the Bio-Europe Spring 2022 and Maxim Group – 2022 Virtual Growth Conferences

Geneva, Switzerland, March 24, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...

ADXN : 7.84 (+0.06%)
Addex Reports Full Year 2021 Financial Results and Provides Corporate Update

CHF20.5M ($22.5M) of cash and cash equivalents at December 31, 2021Dipraglurant Phase 2 blepharospasm clinical trial on track to report data in Q2...

ADXN : 7.84 (+0.06%)
Addex to Present at the Virtual Sachs Associates 3rd Annual European HealthTech and 15th Annual European Life Sciences CEO Forums

Geneva, Switzerland, February 24, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...

ADXN : 7.84 (+0.06%)
Addex to Present at the Swiss Equities Baader Virtual Conference

Geneva, Switzerland, January 11, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...

ADXN : 7.84 (+0.06%)
Addex to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Geneva, Switzerland, January 6 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...

ADXN : 7.84 (+0.06%)
Addex Raises $10.0 Million in Equity Financing

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 17, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage...

ADXN : 7.84 (+0.06%)

Business Summary

Addex Therapeutics Ltd is a clinical-stage pharmaceutical company. It is focused on the development and commercialization of small molecule drugs for neurological disorders. The company's lead drug candidate includes dipraglurant, ADX71149 which are in clinical stage. Its Preclinical programs include...

See More

Key Turning Points

3rd Resistance Point 8.59
2nd Resistance Point 8.44
1st Resistance Point 8.14
Last Price 7.84
1st Support Level 7.69
2nd Support Level 7.54
3rd Support Level 7.24

See More

52-Week High 27.90
Fibonacci 61.8% 19.15
Fibonacci 50% 16.45
Fibonacci 38.2% 13.75
Last Price 7.84
52-Week Low 5.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar